Predix is a drug discovery and development company
Predix is a drug discovery and development company that uses a novel 3D
Discovery and Optimization Engine for GPCR drug candidates and is taking its
novel compounds into the clinic. The discovery engine uses a sophisticated
proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of
any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid
high-throughput in silico screening of millions of compounds against the 3D in
silico model of the target; and an integrated medicinal/computational platform
for lead optimization based on the receptor's structure (ICELR-3D(TM)) and
predictive algorithms for important drug properties. In August, Predix and
Physiome Sciences Inc. combined companies and expanded the expertise into ion
channel drug discovery.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 27, 2005 | Series C | $43M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Yamanouchi Venture Capital | — | Series C |
Novel Bioventures | — | Series C |